Track Cocrystal Pharma, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cocrystal Pharma, Inc. COCP · Stock Open Cocrystal Pharma, Inc. in new tab

0.9801 USD
EPS
-0.76
P/B
12.90
ROE
-311.68
Beta
1.61
Target Price
8.00 USD
Loading chart...
Key Metrics
Earnings dateApril 1, 2027
EPS-0.76
Book Value0.08
Price to Book12.90
Debt/Equity128.45
% Insiders22.404%
Estimates
Forward P/E-2.06
Forward EPS-0.48
Target Mean Price8.00

DCF valuation

Model fair value for Cocrystal Pharma, Inc. (COCP)
Result
Sign in to run the valuation for COCP.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus None · mean target 8.00 USD (low 6.00, high 10.00) · as of 15 Nov 2026
Low 6.00
Mean 8.00
High 10.00
Price 0.9801
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Cocrystal Pharma, Inc. Logo Cocrystal Pharma, Inc. Analysis (COCP)

United States Health Care Official Website Stock

Is Cocrystal Pharma, Inc. a good investment? Cocrystal Pharma, Inc. (COCP) is currently trading at 0.9801 USD. Market analysts have a consensus price target of 8.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Cocrystal Pharma, Inc. is expected to release its next earnings report on April 1, 2027. The market consensus estimate for Forward EPS is -0.48.

Investor FAQ

Does Cocrystal Pharma, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cocrystal Pharma, Inc.?

Cocrystal Pharma, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 1, 2027. The company currently has a trailing EPS of -0.76.

Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.

Exchange Ticker
NMS (United States) COCP
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Jan. 24, 2018 0.03
Oct. 11, 2022 0.08
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion